Monitoring CBC weekly during long-term therapy is recommended
Neonatal:
Reported with duration of therapy > 10 days:
Neonatal: Reversible anemia and thrombocytopenia reported in children, especially those who received prolonged treatment (>14 days)
Reversible, nonselective MAO inhibitor. Check for drug interactions
Neonatal:
Neonatal:
Pediatric: bioavailability 100%
Neonatal:
Antimicrobial class: Oxazolidinone
Average serum half life:
Route of Elimination: